Ellodi Pharmaceuticals Announces Fast Track Designation Granted by the FDA to APT-1011 for the Treatment of Eosinophilic Esophagitis (EoE)
Lawrenceville, N.J.– February 8, 2021 – Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company, today announced that APT-1011 (fluticasone propionate oral disintegrating tablet) has been granted Fast... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 8, 2021 Category: Pharmaceuticals Source Type: clinical trials
TRIMBOW ® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD
Condition: COPD Interventions: Drug: Beclometasone Dipropionate / Formoterol Fumarate / Glycopyrronium 100/6/10 mcg; Drug: Fluticasone Furoate / Vilanterol Trifenatate 100/25 mcg Sponsor: Chiesi Farmaceutici S.p.A. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2020 Category: Research Source Type: clinical trials
